🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση

    Lacuna Pharma Pty Ltd

    Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%

    phase 3 small molecule active

    1 trial

  2. Anifrolumab

    AstraZeneca AB

    Moderate-to-severe Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  3. Anti C5 Complement mAb Placebo, Ultomiris 1,100 mg/11 mL concentrate for solution for infusion

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  4. Anti C5 Complement mAb Placebo, Ultomiris 300 mg/30 mL concentrate for solution for infusion

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  5. Antiplatelet (Aspirin, Dipyridamole, clopidogrel)

    United Therapeutics Europe Ltd

    Cervical Artery Dissection

    phase 3 small molecule completed

    1 trial

  6. Apitox - pure honeybee toxin

    Apimeds Pharmaceuticals US

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  7. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  8. Apremilast, Apremilast, Apremilast, Apremilast placebo product is supplied to the clinic as 10, 20 and 30 mg tablets and 5 mg/mL oral solution. The placebo product is the same as the drug product formulation except there is no active apremilast., Apremilast

    Amgen

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  9. Aripiprazole

    Otsuka Beijing Research Institute

    Bipolar I

    phase 3 small molecule completed

    1 trial

  10. Aripiprazole IM Depot

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  11. Arm A Mylotarg plus DA Versus CPX-351

    Cardiff Oncology

    Acute Myeloid Leukaemia

    phase 3 small molecule active

    1 trial

  12. Armodafinil

    Teva Pharma GmbH

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  13. Armodafinil

    Teva Pharma GmbH

    Narcolepsy

    phase 3 small molecule completed

    2 trials

  14. Armodafinil 100 to 250 mg/day

    Teva Pharma GmbH

    Excessive Daytime Sleepiness

    phase 3 small molecule completed

    1 trial

  15. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Excessive Sleepiness

    phase 3 small molecule completed

    1 trial

  16. Armodafinil 150 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  17. Armodafinil 250 mg/day

    Teva Pharma GmbH

    Obstructive Sleep Apnea

    phase 3 small molecule completed

    1 trial

  18. Arsenic trioxide

    Teva Pharma GmbH

    Acute Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  19. Arsenic trioxide

    Teva Pharma GmbH

    Acute Promyelocytic Leukemia

    phase 3 small molecule completed

    1 trial

  20. Asciminib

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  21. Asenapine Sublingual Tablets 10 mg

    Amneal Pharma Europe Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  22. Asparaginase

    Children's Hospital of Fudan University

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  23. Aspirin® protect 100 mg Magensaftresistente Tablette Acetylsalicylsäure, Aspirin® protect 300 mg Magensaftresistente Tablette Acetylsalicylsäure, Placebo of Aspirine 100 mg protect, placebo of aspirin 300 mg protect

    Pari Pharma GmbH

    Colorectal adenomas, Lynch syndrome

    phase 3 small molecule active

    1 trial

  24. Atogepant, Placebo for atogepant tablets 60mg

    AbbVie Deutschland GmbH & Co. KG

    Migraine

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources